N/A N=10 Correlating Brain Tissue Oxygen and Regional Cerebral Oximetry
Stroke
Primary: Correlation Between Regional Cerebral Oximetry (RSO2) and Cerebral Oxygen Tissue Tension (PbrO2). — .5 Spearman Correlation (rs) Coefficient — p=0.036
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=206 Sorafenib Long Term Extension Program
Neoplasms
Primary: Sorafenib Treatment Duration Within STEP — 15.69; 40.13 Months
Phase 2 N=153 Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202)
Dry Eye
Primary: Symptom Assessment in Dry Eye (SANDE) Questionnaire — 58.95; 57.21; -18.80; -16.60 units on a scale
Phase 2 N=5 LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
Prostate Cancer
Primary: Maximally Tolerated Dose (MTD) (Phase 1b) — NA mg/m^2
Phase 4 N=49 Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma
Asthma
Primary: Area-Under-the-Effect Curve of Percent Change in Test-Day Baseline Forced Expiratory Volume in 1 Second (FEV1) Versus Time (up to 2 Hours Postdose), %FEV1 AUEC0-2…
Phase 1 N=101 Woebot for Substance Use Disorders
Substance Use Disorders
Primary: Change in Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) From Baseline to Post-treatment at 8 Weeks — -9.3 score on a scale
Phase 4 N=46 Regional Anesthesia to Reduce Opioid Use Following Functional Endoscopic Sinus Surgery
Pain Management
Primary: Participant Pain Control — 4.5; 5.87; 4.63; 5.00 units on a scale — p=0.16
Phase 4 N=40 Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD)
Post-Traumatic Stress Disorder
Primary: Clinician-Administered PTSD Scale (CAPS) — 79.1; 81.9; 90.0; 91.0 units on a scale — p=0.286
Phase 4 N=6 Pimavanserin for Insomnia In Veterans With Posttraumatic Stress Disorder
Post-traumatic Stress Disorder · Insomnia
Primary: Recruitment Rates — 1.03 participants enrolled per month
N/A N=24 Transcranial Magnetic Stimulation for Mal de Debarquement Syndrome
Mal de Debarquement Syndrome
Primary: Dizziness Handicap Inventory — -17.5; -3.7; -8.4; -10.1 score on a scale — p=0.0439
Phase 4 N=17 Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients
Peritoneal Dialysis Complication · Hyperphosphatemia · Hypoalbuminemia
Primary: Serum Phosphate at Baseline — 7.47 mg/dL
Phase 4 N=32 Prophylactic Antibiotics in Admitted Cirrhotics
Cirrhosis, Liver
Primary: Infections — 2; 5 Participants
N/A N=239 CARES: A Mobile Health Program for Alcohol Risk Reduction
Alcohol Abuse
Primary: Drinks Per Week — 4.05; 5.58 drinks
Phase 2 N=6 Prebiotics and Metformin Improve Gut and Hormones in Type 2 Diabetes in Youth (MIGHTY-fiber)
Diabetes
Primary: Gastrointestinal (GI) Tolerability Score — 2.31; 2.63; 2.70; 2.71 score on a scale
Phase 3 N=20 Sodium Bicarbonate Supplementation in Chronic Kidney Disease Evaluation of Dose Response, Safety and Beneficial Effects
Chronic Kidney Disease
Primary: Serum Bicarbonate Levels — 25.5; 22.2 mEq/L